ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2021年07月19日 09時00分
Source:
Eisai
エーザイ、米国におけるADUHELM(TM)の状況について発表
東京, 2021年07月19日 - (JCN Newswire) - 当社は、本剤の承認ならびにそれを裏付ける臨床試験データを支持しており、臨床現場の医療従事者の方々に、添付文書の内容について十分にご理解をいただけるよう情報提供活動に取り組んでいます。現在、医療機関におけるADUHELM(TM)(一般名:アデュカヌマブ)の処方の推進と本剤の投与可能なインフュージョンセンターの拡大等を含めた当事者様への薬剤アクセス環境の整備に全力で取り組んでいるところであります。これらの諸活動により、本剤の治療対象となる全ての当事者様に本剤をお届けできることを期待しています。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2021/news202158.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
TANAKA PRECIOUS METAL TECHNOLOGIES establishes total solutions system for contract manufacturing of various test kits including in vitro diagnostics
Feb 05, 2026 22:00 JST
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013
Feb 05, 2026 11:55 JST
Hitachi significantly expands exhibits at the "Hitachi Building Solutions Lab", a research facility for collaborative creation with customers
Feb 05, 2026 11:48 JST
Japantastics Launches Global Curator Platform Bringing Japan Craftsmanship to the World
Feb 04, 2026 22:00 JST
The 55-Point Gap: Measuring What Matters in Automotive Impact
Feb 04, 2026 18:00 JST
Mitsubishi Heavy Industries Announces Large Order Intake, Revenue, and Profit Growth in First Three Quarters, Raises Full-Year Guidance
Feb 04, 2026 17:13 JST
Honda Co-developing Automobile SoC with U.S.-based Mythic to Accelerate Research to Enhance AI Computing Performance and Energy Efficiency
Feb 04, 2026 11:32 JST
DENSO Announces Third Quarter Financial Results
Feb 03, 2026 19:36 JST
FWD Group survey reveals over 70 per cent of Asia's middle-class feel anxiety about financial wellbeing, preventing longer-term planning
Feb 03, 2026 15:13 JST
Fujitsu's Takane LLM successfully piloted in central government agency to streamline public comment operations
Feb 03, 2026 11:14 JST
EAGLE Trial Shows Olympus(R) CADDIE(TM) AI Solution Aids in the Detection of High-Risk and Hard-to-Detect Colorectal Lesions
Feb 03, 2026 10:00 JST
SGL Golf Launches in U.S. Market to Meet Demand for Autonomous Course Management Solutions
Feb 03, 2026 03:00 JST
Lockheed Martin and Fujitsu to accelerate dual-use technology development
Feb 02, 2026 16:29 JST
Fujitsu introduces biometric authentication service for SMBC Nikko Securities Online Trading
Feb 02, 2026 14:30 JST
JCB Launches Usage Promotion Campaign for Inbound Visitors in Fukuoka's Tenjin Area
Feb 02, 2026 10:00 JST
NTT DOCOMO Concludes Partnership Agreement with Aduna to Advance Global Network API Expansion
Jan 30, 2026 22:50 JST
ANIME TOKYO STATION ON ROBLOX: Commemorating the One-Year Anniversary with Gifts and a Wealth of Add-on Content
Jan 30, 2026 09:00 JST
MAZDA CX-5 Achieves Five Million Units in Global Production and Sales
Jan 29, 2026 16:15 JST
The Executive Centre Celebrates 25 Years in Japan: A Commitment to Long-Term Growth and Investment
Jan 29, 2026 12:00 JST
Hitachi reinvents Ellipse Enterprise Asset Management (EAM) solution with Microsoft's AI-enabled technology to improve critical infrastructure resilience
Jan 29, 2026 10:14 JST
More Latest Release >>
Related Release
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
1/26/2026 11:37:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
1/21/2026 4:44:00 PM JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
1/13/2026 9:50:00 AM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
1/6/2026 10:43:00 AM JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
12/11/2025 7:41:00 PM JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
12/9/2025 6:51:00 PM JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
12/4/2025 6:36:00 PM JST
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
12/3/2025 6:19:00 PM JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
12/3/2025 12:01:00 AM JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
11/28/2025 11:00:00 PM JST
More Press release >>